ROCKVILLE, Md., Oct. 15, 2025 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: Chardan’s 9th Annual Genetic Medicines Conference Panel “Battleground States for Muscular Dystrophies”: Tuesday, October […]
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase […]
– Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md., Nov. 14, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today […]
ROCKVILLE, Md., Aug. 8, 2024 /PRNewswire/ — REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on Thursday, August 15, 2024. H.C. Wainwright 4th Annual Ophthalmology […]
